[Choriogonadotrophic hormone and placental tumors].
The radioimmunological dosage of choriogonadotrophic hormone is the actual basis for the choice of patients to be treated, to recognize the poor prognosis cases, to adjust the treatment in drugs, doses and durations, to detect the relapses. The clinicien must obey the biologist who is always right.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002822:Choriocarcinoma / Q000175:diagnosis* / Q000628:therapy; D006063:Chorionic Gonadotropin / Q000032:analysis*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006828:Hydatidiform Mole / Q000175:diagnosis* / Q000628:therapy; D009364:Neoplasm Recurrence, Local; D011247:Pregnancy; D014594:Uterine Neoplasms / Q000175:diagnosis* / Q000628:therapy
D000970:Antineoplastic Agents; D006063:Chorionic Gonadotropin
L'hormone choriogonadotrophine et les tumeurs placentaires.